Cardiology 2013

Notes: De Backer, Daniel

ENG

London, England

2013/11/26 06:00

Crit Care. 2013 Nov 22;17(6):247.

URL: http://www.ncbi.nlm.nih.gov/pubmed/24267398

Author Address: Department of Intensive Care, Erasme University Hospital, Universite Libre de Bruxelles, B-1070, Brussels, Belgium. ddebacke@ulb.ac.be.

 

 

Reference Type:  Journal Article

Record Number: 460Author: de Boer, S. P., van Leeuwen, M. A., Cheng, J. M., Oemrawsingh, R. M., van Geuns, R. J., Serruys, P. W., Boersma, E. and Lenzen, M. J.

Year: 2013

Title: Trial participation as a determinant of clinical outcome: differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology

Journal: Int J Cardiol

Volume: 169

Issue: 4

Pages: 305-10

Date: Nov 15

Short Title: Trial participation as a determinant of clinical outcome: differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology

Alternate Journal: International journal of cardiology

ISSN: 1874-1754 (Electronic)

0167-5273 (Linking)

DOI: 10.1016/j.ijcard.2013.09.011

Accession Number: 24144926

Abstract: BACKGROUND: This study examines differences in clinical outcome between trial-participants and non-participants after percutaneous coronary intervention (PCI). METHODS AND RESULTS: This study compromised of 11,931 consecutive patients who underwent PCI in a high volume center, during the period 2000 – 2009. Of these patients, 1787 (15%) participated in an interventional clinical trial with a follow-up period of at least six months. The maximum follow-up duration was 11.8 years, with a median of 3.8 years (IQR: 2.6 – 6.5). Baseline and procedural characteristics differed between trial-participants and non-participants. Trial-participants were more often male, were younger, had more cardiovascular risk factors and were treated more often for stable angina pectoris and single vessel disease. Overall mortality at maximum follow-up was lower for trial-participants compared to non-participants (8.1% versus 17.6%, p<0.001, adjusted HR, 0.62, 95% CI: 0.52-0.74). There was no difference in the incidence of non-fatal MI and CABG. Repeat PCI was seen more often in trial-participants (18.1% versus 30.7%, p<0.001, adjusted HR 1.91, 95%CI 1.73-2.10). Consequently, a higher incidence of the composite of mortality, repeat revascularization, and non-fatal MI was seen in the trail-participants (adjusted HR.1.36 95% CI 1.25 – 1.47), but this association was primarily driven by the occurrence of repeat PCI. CONCLUSION: Participants in clinical trials in the field of interventional cardiology with a follow-up of at least six months differed considerably from non-participants in baseline and procedural characteristics. Trial-participants had better survival than non-participants. In contrast, a two-fold higher incidence of repeat PCI was observed in trial-participants.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208